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https://doi.org/10.1016/j.stemcr.2018.06.012SUMMARYThe human pluripotent stem cell (hPSC) research landscape is rapidly evolving. To assess possible novel trends in hPSC usage, we
analyzed experimental hPSC research published from 2014 to 2016 and compared our data with those of earlier periods. The number
of papers describing experimental work involving hPSCs increased further with clear differences in the scientific impact of publications
from different countries. Our results confirm the leading position of US-based hPSC research, although to a lesser degree than observed
previously. Our data reveal that research into human induced pluripotent stem cells alone surpassed human embryonic stem cell (hESC)
research by 2015 and rapidly grew after that.We also report on continuing and even slightly growing research activities in the hESC field
as well as on a generally declining rate of the generation of new hESC lines. An increasing portion of new hESC lines represents disease-
specific and clinical-grade cell lines. The previously noted usage of only a few early established hESC lines in the vastmajority of scientific
work is sustained. We also provide a comprehensive overview on clinical trials on the basis of hPSCs. We find that the vast majority of
those trials are based on hESC-derived cell products that were generated from an only limited number of relatively old cell lines.INTRODUCTION
Since the first derivation of human embryonic stem cells
(hESCs) in 1998 (Thomson et al., 1998), research has
focused on a better understanding of the unique charac-
teristics of these cells and on a future use of hESC deriva-
tives for cell replacement therapies. However, derivation
and use of hESCs has been controversial due to the origin
of these cells from human extracorporeal embryos, which
are usually destroyed in the process of hESC derivation.
With the first establishment of human induced pluripo-
tent stem cells (hiPSCs) in 2007 (Takahashi et al., 2007;
Yu et al., 2007) the debate has been raised again. hiPSCs
share fundamental characteristics of hESCs but are not
burdened with the embryonic origin of hESCs. Since
hiPSCs are derived from somatic cells, they can be easily
used to establish any disease-specific cell line for analysis
of cellular processes during pathogenesis as well as for
development of novel agents and drugs. Moreover,
because of the option to produce hiPSCs for any diseased
individual, they are expected to have advantages over
hESCs in future cell and tissue replacement therapies
with respect to immune rejection. Some initial disadvan-
tages of hiPSCs, such as dependence on use of retroviruses
for reprogramming, have meanwhile been overcome,
while others, such as high variability in differentiation
potential and genetic stability, still remain subjects of
intense research. However, faced with an alternativeStem Cell
This is an open access article under the Csource for human pluripotent stem cells (hPSCs), it was
widely discussed whether hiPSCs would replace hESCs
in research and whether hESCs would be exclusively
needed to verify the pluripotency of hiPSCs only for a
transition period (Holm, 2008; Hyun et al., 2007; Power
and Rasko, 2011; Sipp, 2009).
We and others have studied research trends in the field of
human pluripotent stem cells over the past 12 years (Guhr
et al., 2006; Lo¨ser et al., 2010; Negoro et al., 2017; Owen-
Smith and McCormick, 2006). Recently, we reported that
research with hESCs did not decline but rather broadened
from 2008 to 2013 despite the availability of hiPSCs
(Kobold et al., 2015). Moreover, we observed a diversifica-
tion of the research fields in which hESCs and hiPSCs
were used to answer partially different research questions.
In the current report, we extended this analysis to cover
more recent developments. By evaluating all original
research papers, which report results of experimental use
of hPSCs, we show that there is a considerable increase in
hiPSC research while research with hESCs grows only
slightly. Furthermore, there is an only limited overlap of
both research fields. We also present data on hESC line
usage in experimental research and found that the increase
in hESC research over the past 10 years is not linked to a
considerable rise in the derivation of novel hESC lines.
We also present an overview on current clinical trials
involving hPSC-derived cell products and investigate the
cell line usage in these trials.Reports j Vol. 11 j 485–496 j August 14, 2018 j ª 2018 The Authors. 485
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Figure 1. Worldwide Research in Human Pluripotent Stem Cells
(A) Number of original research papers published from 2014 to
2016. Included are all studies in which experimental use of hESCs
(left) or/and hiPSCs (right) is reported.
(B) Number of research papers published on experimental use of
hESCs (left) or/and hiPSCs (right) in the 3-year periods indicated.
The number of papers in which both hESCs and hiPSCs were used in
the same study is shown in lighter gray. Mere gold standard usage
of hESCs is indicated by gray-white striped lines.RESULTS
Data Acquisition
Over the past years we have established a vast validated
database on publicly known hESC lines and on original
scientific papers reporting experimental use of hPSCs.
This manually validated database was established by
annual searches of the PubMed database for relevant litera-
ture and now contains data onmore than 1,500 hESC lines
published in peer-reviewed papers. In addition, we have486 Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018documented more than 3,300 and about 1,400 papers
that were published by end of 2013 and reported on exper-
imental use of hESCs or hiPSCs, respectively. Using the
search routines described earlier, we intended to identify
hPSC research papers that were published in the more
recent past, namely from 2014 to 2016. Our search resulted
in 7,597 primary hits for hESC-related studies and 6,359
primary hits for hiPSC-related studies. Of those, we
excluded papers that were categorized by PubMed as non-
experimental research (Comments, Editorials, Reviews,
etc.). We also excluded studies that appeared in journals
that usually do not report original research.We thenmanu-
ally inspected the abstracts or/and full texts of the remain-
ing 4,118 hESC-related and 3,370 hiPSC-related papers and
identified 1,799 and 2,162 original research papers that
report on the experimental use of hESCs or hiPSCs, respec-
tively. Since 676 papers reported experimental use of both
hESCs and hiPSCs (‘‘overlap’’), a total of 3,285 original
publications were examined in the analyses described
below. In addition, we found that in 43 or 171 studies
(usually commercially available) cell derivatives of hESCs
or hiPSC were used, respectively. These studies were not
included in the subsequent analyses for reasons detailed
in Kobold et al. (2015).
Number and Origin of hPSC Research Papers
We first intended to determine the number and origin of
research papers that involved experimental use of hESCs
and hiPSCs. Figure 1A shows the results of the respective
analysis for the past 3 years (2014–2016). In 2014, the num-
ber of research papers reporting on hiPSCs equaled the
number of hESC studies for the first time. In the following
2 years, the hiPSC paper count clearly surpassed that of
hESC papers. Whereas the number of research papers
involving hESCs raised only slightly by about 7% from
2014 to 2016, the count of published hiPSC studies
increased by more than 55% during the same period.
When these numbers were compared to those of the pre-
ceding 3-year periods (2008–2010 and 2011 to 2013,
respectively), an increase in the number of both hESC
and hiPSC research papers by 51.0% and 70.9%, respec-
tively, was noted (Figure 1B). The strong increase in hiPSC
research papers clearly indicates the enormous interest in
these cells but is also a consequence of the relative novelty
of this research field, in which only few publications were
produced from 2008 to 2010. We also noted that there is
a considerable number of studies in which both hESCs
and hiPSCs were used (light gray and gray/white striped
portions of the bars in Figure 1B). Closer inspection of
stem cell usage in these papers revealed that the number
of papers in which hESCs were used for mere comparison
to verify certain characteristics of hiPSCs (‘‘"gold standard’’
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Figure 2. Allocation of hPSC Research to Specific Countries
Share (percentage) of papers from a given country in relation to the total number of hESC research papers (A) and hiPSC research papers (B)
for the indicated periods. Only results for countries with more than 50 or 30 original publications in the hESC or hiPSC field, respectively,
were included. The numbers to the right of the upper bars relate to the total 9-year period (2008–2016).markedly decreased during the last years indicating that,
despite the growth of the hiPSC field, hESCs are still an in-
dependent research object. In addition, nine of the hESC
studies identified here also report on derivation/experi-
mental use of pluripotent stem cells derived from embryos
produced by somatic cell nuclear transfer.
We next wished to examine the origin of research papers
in the hPSC field. About 70% of papers in both the hESC
and hiPSC fields were authored by scientists from only
one country, while in about 30% authors from laboratories
based in at least two countries contributed to the publica-
tion. As in our earlier studies, we assigned the latter papers
to the country of the corresponding author and excluded
papers from the hESC paper pool where hESCs were used
for mere comparison with hiPSCs (‘‘gold standard’’ use of
hESCs; for example, when novel hiPSC lines were gener-
ated and investigated for their pluripotency in comparison
with hESCs, 113 papers for the 2014 to 2016 period). From
2014 to 2016, research groups from 40 nations published
results of hESC research, while hiPSC research papers
came from groups based in 37 countries. Most papers pub-
lished in both research fields came from US-based groups,
followed by groups from China, the UK, Japan, and Korea
(hESC field) and by Japan, China, Germany, and the UK
(hiPSC field), respectively. To reveal longer-term trends inthe contribution of groups from specific nations to hPSC
research, we combined our new data for the 2014 to 2016
period with data collected for the years 2008 to 2013
(Kobold et al., 2015) (Figure 2). This analysis confirmed
thatmost of the 4,744 hESC research papers published dur-
ing the whole period came from research groups based in
the United States (40.5% of all research papers worldwide),
followed by groups from China (9.2%), the United
Kingdom (7.6%), Japan (4.7%), and South Korea (4.1%, Fig-
ure 2A). It should be noted that the US contribution to
worldwide hESC research decreased by 15.8% (from
44.3% in the 2008 to 2010 period to 37.3% in the 2014
to 2016 period), whereas the contribution of scientific
groups from China increased by 58.6% in the same period
(from less than 7%–11.1%). With respect to the 3,544
hiPSC papers published during the whole period, we also
noted a sustained leading position of US-based research,
which contributed with 41.9% to worldwide published
hiPSC research, followed by Japan (14.6%), China (8.3%),
Germany (6.3%), and the United Kingdom (4.4%, Fig-
ure 2B). As in the hESC field, a relative decrease by nearly
30% in the contribution of US research groups was noted
(from 53% in the 2008 to 2010 period to about 37.3% in
the 2014 to 2016 period), whereas the relative contribution
of groups from China and Germany markedly increased.Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018 487
Table 1. Impact of Research in Human hPSC Published from
2013 to 2015








Canada 12.377 Canada 15.503
Netherlands 9.885 Israel 12.709
United States 9.422 Netherlands 11.605
Israel 9.389 United States 10.170
France 8.943 Spain 9.695
Total average 7.749 France 8.650
Singapore 7.594 United Kingdom 8.522
United Kingdom 7.585 Total average 8.223
Germany 7.345 Australia 7.482
Japan 6.992 Italy 7.445
Sweden 6.647 Korea 6.840
Spain 6.381 Germany 6.799
Korea 6.055 Singapore 6.174
Belgium 6.054 Sweden 5.820
China 4,961 Japan 5.794
Australia 4.892 China 5.247
Finland 4.068 Finland 4.244
Iran 2.836 Iran 2.544
The 2016 5-years impact factors of the journals that published experimental
hESC or hiPSC research papers, respectively, from the countries indicated
were summed and divided by the number of research papers from the respec-
tive country. In case of hESC papers, work in which hESCs were only used as
gold standard for hiPSC research was omitted. Only research from countries
with at least 20 hESC and 15 hiPSC research papers, respectively, was
included.Impact of hPSC Research Papers
Next we assessed the scientific impact of published hPSC
research from specific countries. Since reliable and compa-
rable citation frequencies are not yet available for papers
published in 2016, those papers were not included in the
analysis. Instead, we included in our analysis papers pub-
lished in 2013 since the impact of these papers has not
been assessed so far. Thus, the period from 2013 through
2015 was assessed here.
We first determined the average journal impact factor
provided by the Institute for Science Information (ISI) for
journals that published hESC and hiPSC studies from
2013 to 2015. The weighted overall average 2016 5-year488 Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018impact factor for journals that had published experimental
hESC work was 7.749, while journals that published hiPSC
research had an average impact factor of 8.223, indicating a
sustained scientific interest in hPSC research. The average
impact of papers from specific countries is summarized
in Table 1. As already reported for earlier research
periods, hPSC research from countries such as Canada,
the Netherlands, Israel, or the United States was published
in more influential journals than studies published by
Chinese, Japanese, or Korean groups.
However, the impact factor of a journal does not neces-
sarily mirror the actual citation numbers of individual
papers published in the respective journal. Therefore, we
analyzed, as a more reliable measure for the impact of
research, the average frequencies at which hESC and
hiPSC research papers were cited through the end of
2017. For this purpose, the citation numbers for each pa-
per were determined using the Web of Science database
and weighted according to the date of publication.
Average citation frequencies per year of papers from
selected countries are shown in Table 2. Although there
are minor differences in comparison with the data shown
in Table 1, the results in principle confirm the high influ-
ence of research published by groups from Canada, the
Netherlands, the United States, and Israel in both research
fields. Unexpectedly, hESC research from Japan and
Germany over-performed with respect to actual citation
frequencies, while the impact of hiPSC research from
both countries is lower than average. This is surprising,
because hiPSC research is highly supported in these coun-
tries, while use of hESC is strictly regulated, especially in
Germany. To ascertain that the diversity in average cita-
tion frequencies among papers from several countries is
not caused by only a few popular and extremely highly
cited papers, we grouped studies according to their
citation frequency per year (Tables S1 and S2). While
the percentage of all papers in the hESC and hiPSC field
that were cited more than 15 times per year was less
than 15%, the proportion of papers from Canada, the
Netherlands, and the United States that were cited at
high rates was clearly higher. Therefore, a rather broad
range of hPSC papers contributes to the high citation fre-
quency of research from these countries.
Application of hESC Lines in Research
Over the past decade, we and others reported the predom-
inant use of only a fewhESC lines in experimental research,
which were derived early in the field (Guhr et al., 2006;
Lo¨ser et al., 2010; McCormick et al., 2009; Scott et al.,
2009). However, while some supposed that this phenome-
non was caused by a long-lasting and trans-national effect
of the research policy of the Bush administration (Scott
et al., 2009), we demonstrated more recently that it can
Table 2. Average Citation Frequencies per Year of hPSC
Research Papers










Netherlands 13.6 Canada 13.8
United States 12.2 United States 13.8
Canada 11.6 Israel 13.3
Germany 10.1 United Kingdom 12.0
Japan 9.7 Australia 11.9
United Kingdom 9.5 Netherlands 11.2
Total average 9.2 Total average 10.7
Israel 8.8 Spain 9.3
France 7.6 Germany 8.9
Singapore 7.3 Japan 8.6
Korea 6.9 Italy 7.8
Sweden 6.3 Sweden 7.3
Spain 5.1 Singapore 6.4
Australia 5.0 Korea 6.3
Belgium 4.9 France 6.3
China 4.9 China 6.1
Finland 4.3 Finland 5.1
Iran 2.9 Iran 3.4
Citation numbers were determined using the Web of Science database, and
data were normalized as described in the Experimental Procedures section.
In the case of hESC papers, work in which hESCs were only used as gold stan-
dard for hiPSC research was omitted. Only research from countries with at
least 20 hESC and 15 hiPSC research papers, respectively, was included.be better explained on the basis of power laws (Schuldt
et al., 2013). To elucidate whether there are novel trends
in the application of certain established hESCs, we
analyzed the use of hESC lines in experimental research
published from 2008 to 2016. Inspection of hESC research
papers revealed that application and/or derivation of a total
of 1,419 different hESC lines was reported from 2008 to
2016. Table 3 shows those 21 hESC lines that were used
most frequently in these studies. There was no funda-
mental change in the usage of hESC lines compared with
our earlier studies (Guhr et al., 2006; Lo¨ser et al., 2010;
Schuldt et al., 2013), as expected on the basis of our
power law model. Again, three of the five oldest hESC
lines (WiCell H1 [WAe001-A], H7 [WAe007-A], andH9 [WAe009-A]), already published in 1998, were most
commonly used. These three hESC lines were used in
more than 74% of countries that contributed to hESC
research from 2008 to 2016 (32 of 43 countries). However,
research from countries in which none of these lines were
applied accounted for only 1.5% of total papers. The cell
line H9 was used in more than 2,200 studies published
from 2008 to 2016 (46.4% of all published original research
papers involving experimental use of hESCs), followed by
hESC lines H1 (23.5%), H7 (7.4%), HES-3 (ESIBIe003-A,
6.0%), HUES9 (HVRDe009-A, 3.8%), and BG01
(VIACe001-A, 3.6%). With the notable exception of
HUES9, which was only published in 2004, these hESC
lines as well as five other lines among these top 21 ( H14
[WAe014-A], HES-2 [ESIBIe002-A], HSF-1 [UCSFe003-A]
and HSF-6 [UCSFe002-A], and H13 [WAe013-A]) were
already available to NIH-funded US researchers before the
change in the US stem cell policy under the Obama admin-
istration, supporting our earlier notion that this political
shift had little impact on established stem cell usage
patterns.
To examine whether the predominant use of only a few
well-characterized hESC lines is mirrored by a possible
long-lasting decrease in the derivation of novel hESC
lines, we next determined the number of hESC lines
derived from IVF embryos and published during the
9-year period from 2008 to 2016. hESC lines that were
produced from nuclear transfer embryos or entities
derived by parthenogenetic activation of human oocytes
were not included in our analyses. By November 2009,
1,071 such original hESC lines were publicly known,
and nearly 694 (64.8%) of them were published in peer-
reviewed English-language journals listed in the PubMed
database (Lo¨ser et al., 2010). By 2016, at least 2,168 orig-
inal hESC lines were publicly known, 1,544 (71.2%) of
which were published in peer-reviewed journals. To un-
veil possible trends in the time course of hESC derivation,
we inspected hESC research papers published from 2008
to 2016 for reports on derivation of novel hESC lines or
on the use of (novel) hESC lines that were not used in pre-
viously published research, respectively. The results of the
analysis are shown in Figure 3. Although 566 novel hESC
lines were reported in the scientific literature published
from 2008 to 2010, this number decreased to 301 and
220 for the following 3-year periods 2011 to 2013 and
2014 to 2016, respectively (Figure 3A). Notably, an
increasing percentage of the novel lines were either
derived from pre-implantation genetic diagnosis embryos
to model genetically inherited diseases (disease-specific
hESC lines) or were produced for future clinical applica-
tions (clinical-grade hESC lines; Figure 3B). Thus, the
availability of well-characterized hESC lines that are
accepted and broadly used by the scientific communityStem Cell Reports j Vol. 11 j 485–496 j August 14, 2018 489





2008–2010 2011–2013 2014–2016 Total (2008–2016)
Number
of Papers % of Papers
Number
of Papers % of Papers
Number
of Papers % of Papers
Number
of Papers % of Papers
H9* WAe009-A 495 41.5 847 48.4 860 47.8 2202 46.4
H1* WAe001-A 289 26.9 411 23.5 414 23.0 1114 23.5
H7* WAe007-A 93 8.7 136 7.8 122 6.8 351 7.4
HES-3* ESIBIe003-A 80 7.4 104 5.9 103 5.7 287 6.0
HUES9 HVRDe009-A 60 5.6 64 3.7 54 3.0 178 3.8
BG01* VIACe001-A 81 7.5 60 3.4 31 1.7 172 3.6
HES-2* ESIBIe002-A 60 5.6 67 3.8 45 2.5 172 3.6
KhES-1 KUIMSe001-A 37 3.4 52 3.0 45 2.5 134 2.8
HUES7 HVRDe007-A 31 2.9 35 2.0 34 1.9 100 2.1
KhES-3 KUIMSe003-A 24 2.2 47 2.7 25 1.4 96 2.0
HSF-6* UCSFe002-A 44 4.1 31 1.8 17 0.9 92 1.9
H14* WAe014-A 27 2.5 35 2.0 23 1.3 85 1.8
HUES6 HVRDe006-A 16 1.5 33 1.9 26 1.4 75 1.6
HUES1 HVRDe001-A 28 2.6 22 1.3 17 0.9 67 1.4
HUES3 HVRDe003-A 23 2.1 26 1.5 17 0.9 66 1.4
HUES8 HVRDe008-A 17 1.6 20 1.1 28 1.6 65 1.4
HS181 KIe001-A 29 2.7 20 1.1 12 0.7 61 1.3
HSF-1* UCSFe003-A 25 2.3 23 1.3 8 0.4 56 1.2
MEL-1 SCSe001-A 12 1.1 24 1.4 18 1.0 54 1.1
CA1 MSHRIe001-A 16 1.5 24 1.4 10 0.6 50 1.1
H13* WAe013-A 17 1.6 23 1.3 8 0.4 48 1.0
Shown are the numbers of papers that report on experimental use of the particular hESC line. The percentage values present the share of publications in
the total number of hESC research papers in the given period. Only results for cell lines that were used in at least 1% of papers published from 2008 to
2016 are shown. Please note that in many studies more than one hESC line was used. Sublines and (genetically modified) derivatives were allocated to
the respective parental hESC line. hESC lines that were derived before August 22nd 2001 are marked with asterisks. hPSCreg, Human Pluripotent Stem
Cell Registry of the European Union.seems to cause a decreasing interest in deriving novel
research hESC lines, and obviously new hESC lines are
produced increasingly for specific scientific and future
clinical applications.
Application of hESC Lines in Clinical Trials
Next we were interested to determine which particular
pluripotent stem cell lines had been used in clinical trials
performed so far that involved hPSC-derived cell prod-
ucts. Since research in hPSCs has resulted in considerable
progress, clinical trials based on such cell products have
been initiated roughly over the past 5 years to test novel
cell-based therapies for the treatment of different patho-490 Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018logic conditions, such as macular degeneration, diabetes
mellitus, or spinal cord injury in humans (Trounson and
DeWitt, 2016; Trounson and McDonald, 2015). An over-
view on clinical studies so far approved based on hPSC-
derived cell products is given in Table 4. Currently (March
2018), there is public information on 29 trials involving
hESC-derived stem cell products, while three trials that
involve hiPSC derivatives have been approved so far.
Most of these studies are aiming at testing of safety and
tolerability of the respective stem cell products in a small
patient cohort. Five of the 29 hESC-based trials are follow-
up studies and two additional already-approved trials were





















































Figure 3. Derivation of New hESC Lines
(2008–2016)
(A) Number of hESC lines that were reported
for the first time in original research papers
during the time periods indicated.
(B) Percentage of disease-specific (light
blue) and clinical-grade (dark blue) hESC
lines in total new cell lines reported in
original research papers during the time
periods indicated.is one clinical trial that is based on pluripotent stem cells
derived from a parthenote. A closer analysis of informa-
tion publicly provided on hESC-based studies revealed
that the stem cell materials used in these clinical trials
are derived from only a few hESC lines (Table S3). To
our knowledge, of the cell lines listed in Table S3, only
HADC102 was established as a clinical-grade cell line
from the start, while the other lines were originally estab-
lished as research-grade lines and only later adapted to
cGMP conditions for clinical use. With respect to hiPSCs,
it is notable that only one of the three trials approved so
far was planned to be performed with autologous cell
products derived from the patient’s own hiPSCs.DISCUSSION
Nearly 20 years after the first publication of the successful
derivation of hPSCs, we report a sustained interest in hESCs
and strongly increasing research activities with hiPSCs. Our
findings are based on amanually curated database of exper-
imental hPSC papers that mirrors the genuine research in
this field. The manual curation avoids the risk of the pres-
ence of non-relevant papers usually found in data pools
based on mere and partially automatized web searches,
which may result in over-estimation of real research activ-
ities (Kobold et al., 2015).
Our analysis of the hPSC landscape shows that research
involving hESCs and/or hiPSCs is still increasing, albeit
with a much faster increase for the hiPSC field. While this
trend can be easily anticipated for hiPSCs, a continuing in-
terest in hESC research cannot necessarily be expected.
hESCs are more difficult to derive than hiPSCs and are
not as easily accessible as hiPSCs for researchers. Conse-
quently, only comparatively few laboratories have their
own hESC lines. Moreover, research in hESCs is controver-
sial for ethical reasons and legally tightly regulated inmany
countries. For example, in Germany, researchers who planto use hESCs have to show that hESCs cannot be replaced
by hiPSCs in their research project before hESC usage will
be approved. Despite this, our data consolidate the previ-
ous finding, that research in hESCs and hiPSCs still existed
independently and only partially overlapped in recent
years.Moreover, use of hESC as amere ‘‘gold standard’’ con-
trol for hiPSC research (which was speculated to be the
main area of application for hESCs after emergence of
hiPSCs) remains a rather small area.
We also detected some changes in regional distribution
of hPSC research. Although US-based scientists consider-
ably contributed to hPSC work published in recent years,
the share of US-based research in worldwide research is
decreasing. In contrast, especially Chinese groups increas-
ingly published in the hESC field, while scientific groups
from Germany increasingly contributed to worldwide
hiPSC research. The growing performance of groups from
these two countries in hESC and hiPSC research, respec-
tively, may be an immediate consequence of extensive
funding programs and strong political support of these
particular types of research.
A general look at the impact of hESC research reveals a
gradual growth of the overall average impact factor from
6.030 in 2005 (Guhr et al., 2006) to 7.422 in 2009 (Lo¨ser
et al., 2010) and 7.749 in the present study. In recent years,
research with the highest impact was published by re-
searchers fromCanada, the Netherlands, the United States,
and Israel, confirming their position from previous years,
while research fromKorea, Singapore, andChina underper-
formed. In addition to real quality differences of research, a
possible publication bias in English-language journals,
especially for groups from Asian countries, may explain
this observation.
Also confirming earlier findings is the high divergence of
the average citation numbers of papers from different
countries, which is a more reliable measure of the actual
relevance of a given publication. Again, we found a pre-
dominance of papers from countries such as Canada, theStem Cell Reports j Vol. 11 j 485–496 j August 14, 2018 491
Table 4. Clinical Trials Based on Human Pluripotent Stem Cells






ischemic heart disease NCT02057900 France
Astellas Pharma Stargardt macular dystrophy NCT01345006 United States
Astellas Pharma advanced dry AMD NCT02463344 United States
Astellas Pharma AMD NCT03178149 not specified
Astellas Pharma AMD NCT01344993 United States
Astellas Pharma Stargardt macular dystrophy NCT02941991 UK
Astellas Pharma Stargardt macular dystrophy NCT01469832 UK
Astellas Pharma Stargardt macular dystrophy NCT02445612 United States
Astellas Pharma macular degenerative disease NCT03167203 not specified
Asterias Biotherapeutics spinal cord injury NCT02302157 United States
Asterias Biotherapeutics spinal cord injury NCT01217008 United States
Cell Cure Neurosciences AMD NCT02286089 Israel, United States
CHA Biotech dry AMD NCT01674829 Korea
CHA Biotech Stargardt macular dystrophy NCT01625559 Korea
Chinese Academy of Sciences dry AMD NCT03046407 China
Chinese Academy of Sciences nonexudative AMD NCT02755428 China
Chinese Academy of Sciences Parkinson’s disease NCT03119636 China
Chinese Academy of Sciences,
Institute of Zoology
dry AMD ChiCTR-OCB-15007054 China
Chinese Academy of Sciences,
Institute of Zoology
retinitis pigmentosa ChiCTR-OCB-15007055 China
Eye Institute of Xiamen University severe ocular surface diseases ChiCTR-OCB-15005968 China
Federal University of Sa˜o Paulo AMD, Stargardt disease,
exudative AMD
NCT02903576 Brazil
Pfizer AMD NCT03102138 UK
Pfizer AMD NCT01691261 UK
Regenerative Patch Technologies dry AMD NCT02590692 United States
Southwest Hospital, China macular degeneration diseases,
not specified
NCT02749734 China
Viacyte diabetes mellitus type 1 NCT03162926 Canada
Viacyte diabetes mellitus type 1 NCT02239354 United States, Canada
Viacyte diabetes mellitus type 1 NCT02939118 United States, Canada
Viacyte diabetes mellitus type 1
with hypoglycemia
NCT03163511 United States
(Continued on next page)
492 Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018
Table 4. Continued
Sponsor Disease(s) (as Indicated) Study ID Country
Clinical Trials Based on hiPSCs
RIKEN exudative AMD UMIN000011929
(based on autologous iPSCs)
Japan
Cynata Therapeutics graft-versus-host disease NCT02923375
(based on allogenic iPSCs)
Australia, UK
Kobe City Medical Center General Hospital neovascular AMD UMIN000026003
(based on allogenic iPSCs)
Japan
Follow-up studies among hPSC-based trials are highlighted with a blue background. Withdrawn studies were not included. Studies that only aim at the deri-
vation of patient-specific hiPSC lines and therapeutic cells thereof (but not at the treatment of patients with these hiPSC-derived therapeutic cells) were not
included either. iPSCs, induced pluripotent stem cells.US, theNetherlands, theUK, and Israel with respect to their
average citation numbers, while the above-average posi-
tion of hESC papers from Germany is a rather unexpected
result since Germany has relatively restrictive hESC legisla-
tion. Interestingly, we noted an average underperformance
of research from Japanese and German groups with respect
to impact in the hiPSC field. This is difficult to explain,
especially for Japan. For this reason, we repeated the cita-
tion analysis using the Scopus database (Elsevier), which
confirmed our results in general (data not shown). One
possible explanation for this phenomenon could be the
comparatively broad and generous funding policy with
respect to hiPSC (but not to hESC) research in both coun-
tries, which might also promote less competitive research
performed by less experienced scientists. This could
possibly reduce the average quality of research, resulting
in a diminished average impact of publications. However,
such a broad funding policy will most likely open hiPSC
research to scientists new in the field who may contribute
substantially to the scientific performance of these coun-
tries in the future.
When looking at the hESC lines actually used in pub-
lished research, our data confirm former results with
respect to hESC usage patterns of only a handful of estab-
lished lines as predicted by our power law model (Schuldt
et al., 2013). Overall, although research with hESC is not
decreasing, the derivation of new lines is regressive. This
is likely due to the existence and widespread use of well-
characterized established lines such as H1, H7, and H9,
and to the emergence of hiPSCs. The use of only few lines
in a large percentage of hESC studies may be of advantage
with respect to the comparability and reproducibility of re-
sults. On the other hand, the dominance of only a few
hESC lines in research is accompanied by a lack of universal
applicability of results as well as by genetic under-represen-
tation and dependence on only a few suppliers.
Additionally, our findings are in good agreement with
data obtained from the hPSC registry of the EuropeanUnion (hPSCreg, https://hpscreg.eu) (Seltmann et al.,
2016). According to the data in hPSCreg, the generation
of new hESC lines increased and peaked in the 2005 to
2007 period, after which the numbers of newly derived
lines started to decrease. We found that a large portion of
hESC lines published in the past decade were generated
for specific purposes such as to provide disease models or
to generate clinical-grade lines.We are aware that the actual
number of hESC lines cannot be determined since only
limited information is publicly available. In this study, we
therefore focused on hESC lines published in the peer-
reviewed scientific literature since we consider this a reli-
able measure for quality and accessibility of hESC lines. It
should also be noted that there is frequently a gap between
derivation and publication dates of hESC lines. Conse-
quently, our data reflect the time points of availability of
new hESC lines to the scientific community rather than
the dates of their derivation.
A quantitative assessment of trends in hiPSC derivation is
almost impossible. We noticed that the increasing conve-
nience of hiPSC derivation has caused many laboratories
to establish their own hiPSCs. However, in many cases,
only limited information on the exact number and the de-
gree of characterization of derived hiPSC lines is provided in
published research. In addition, the naming of lines is
frequently ambiguous and, in a range of cases, well-charac-
terized lines and picked clones cannot be discriminated
from the data presented in the respective papers. A recently
proposed standard nomenclature for hPSC lines would be
required to trace the cells and their data (Kurtz et al.,
2018). However, based on our analysis of more than 3,500
hiPSC research papers, we estimate that the number of
hiPSC lines published in the literature up to now exceeds
10,000 by far,many of themderived frompatients suffering
fromgenetic diseases. In addition, there are commercial and
academic hiPSC banks that host thousands of hiPSC lines,
although the degree of characterization of specific cell lines
is not clear in many cases (De Sousa et al., 2017). hPSCregStem Cell Reports j Vol. 11 j 485–496 j August 14, 2018 493
currently registers approximately five times more hiPSC
than hESC lines, reflecting the ratio and an increasing num-
ber of hiPSC lines versus a rather stable number of registered
hESC lines (S.S. et al., unpublished data).
One of the major promises of hPSC is their clinical appli-
cation in regenerative therapies. We provide a comprehen-
sive overview of clinical trials that have been performed so
far based on hESC- and hiPSC-derived cell products. Our
data are based on an intensive long-term observation of
the field and collection of publicly available information
over the past 7 years. However, it should be noted that
some of the clinical trials listed in Table 4 are performed un-
der the clinical research study pathway, which may not
directly lead to a new medical product marketing registra-
tion. These and other studies, which are performed in the
frame of specific ‘‘regenerative medicine’’ regulatory frame-
works, have the potential to speed up the clinical transla-
tion of hPSC research in an academic setting but may not
directly result in applicable cell products. This is different
for the often commercially driven clinical trials that are
performed under the formal "clinical trial" pathway super-
vised by the national drug regulatory agencies. It should
also be noted that simply searching clinical trial registries
for the term ‘‘hiPSC’’ usually results inmany hits. However,
an analysis of the respective trials reveals thatmost of them
only refer to the production of clinical-grade hiPSC lines
from specific patients but not to a treatment of patients
with hiPSC-derived therapeutic cells. These studies were
therefore not included in our results, but it shows that a
dedicated clinical trial registry for hPSC-based studies is
highly desirable for ethical reasons to provide transparency
and avoid replication (Fortunato et al., 2018). Our data
show that most studies performed so far use hESCs, most
likely because these cells have been available for a longer
period, and their derivation is not complicated by addi-
tional reprogramming manipulations. The hESC-based
clinical studies are performed with very few, mostly older
lines. However, we also found publicly available informa-
tion on at least 11 additional planned hPSC-based studies,
four of them using hESCs. Since newer, clinical-grade hESC
lines are available now, it will be interesting to see whether
hESC usage patterns will be sustained in clinical studies as
well, or whether these new lines will replace older lines
quickly.
One of the major advantages of hiPSCs is the potential
for autologous application. However, the only study using
autologous hiPSC lines was put on hold because of
mutations of unknown potential risk in the hiPSC source
material (Garber, 2015). This study was continued with
allogeneic, HLA-matched hiPSCs. Whether autologous,
personalized hiPSCs, or HLA-haplobanks of hiPSC lines,
will become an affordable option for personalized medi-
cine remains disputable (Blair and Barker, 2016). Since494 Stem Cell Reports j Vol. 11 j 485–496 j August 14, 2018HLA matching will not be perfect in the majority of cases,
lifelong immunosuppression may be unavoidable. Unless
affordable technologies for autologous clinical hiPSC use
will be developed, their allogenic use will most likely
diminish the effects of the biggest advantage of hiPSCs
over hESCs for cell therapy applications.
In conclusion, we have shown a continuing parallel
research at high level and impact with hESCs and hiPSCs,
while the increase in published research with hiPSCs accel-
erates faster than that of hESC research, surpassing those by
2015. While hESC usage patterns remained unchanged
over the past decade, the derivation of new hESC lines for
disease modeling and clinical application may foreshadow
a similar trend for hiPSC research, although data to assess
these tendencies are difficult to obtain and would need
centralized resources, common standards for characteriza-
tion, and traceable nomenclature. However, we expect
that the hiPSC usage patterns will be less pronounced
than that observed for hESC lines in research since hiPSCs
are much easier to obtain. As the field is consolidating, we
predict a trend toward a more diverse source of hESC and
hiPSC lines required for tailored applications; e.g., to reflect
human and disease diversity, or to improve safety by using
dedicated clinical-grade lines in clinical trials.EXPERIMENTAL PROCEDURES
Paper Selection
The publication repositories for experimental work involving
hESCs and/or hiPSCs used for former analyses were described in
Kobold et al. (2015).We extended these repositories to papers pub-
lished from 2014 to 2016 by searches of the PubMed database
accessible through the NIH National Library of Medicine using
the search strings described earlier (Guhr et al., 2006; Muller
et al., 2010) with slight modifications of the search string to iden-
tify papers involving hiPSCs. All papers were inspected manually
for use of hESCs and hiPSCs, respectively, before they were added
to the repositories, and studies that exclusively used pluripotent
stem cells from species other than human (e.g., mouse, primates)
were removed. Our hPSC paper repositories therefore only contain
original research papers in which hESCs and/or hiPSCs were used
experimentally. Review papers, news, comments, and editorials,
as well as studies on legal and ethical aspects of research in human
pluripotent stem cells, were not included. The paper repository
contains neither methodical reviews and previously published
protocols nor papers that describe experimental work that exclu-
sively used stem cells derived from embryos produced by nuclear
transfer or from entities produced by parthenogenetic activation
of human oocytes. Studies in which pluripotent stem cell-derived
material (such as hESC RNA) or cells (such as hiPSC-derived cardi-
omyocytes) were not included either. The same applies to studies
in which data obtained in previous research (such as expression
data available from the GEO database) were used. Papers that
were only pre-published in 2016 (but appeared in print in 2017
or later) were not considered. The decision on the assignment of
hESC use to the category ‘‘gold standard’’ application was made by
using the criteria described before (Kobold et al., 2015). Allocation
of a paper to a country was done according to the corresponding
author’s affiliation. Detailed search strings are available on request.
Determination of Weighted Average Impact Factors
and Citation Numbers
Determination of weighted average impact factors was performed
using the 2016 5-year impact factors published by the Journal Cita-
tion Reports (Clarivate Analytics). Of 828 journals that published
experimental work on hPSCs from 2014 to 2016, 95 (11.4%) had
not been judged by the ISI, affecting 103 papers extracted by our
searchmethod (3.1%). These papers were not included in the anal-
ysis. The 5-year impact factor for each journal was multiplied by
the number of papers thatwere published in the respective journal.
The results were summed and divided by the total paper numbers
to obtain the average 5-year impact factor.
Citation numbers were determined by using the Web of Science
database (Clarivate Analytics). Average annual citation frequencies
of papers published in journals with an impact factor were calcu-
lated by dividing the citation number by the number of years after
the study was published (e.g., for a study that was published in
2013, number of citations from 2014 to 2017 was summed and
divided by 4).
Determination of hESC Line Numbers and Usage
Information on hESC lines reported by the end of 2009 is based on
data published previously (Lo¨ser et al., 2010). Information on
novel hESC lines was collected from the scientific papers identified
in this study and by Kobold et al. (2015). In addition, registries
and stem cell banks were screened for the appearance of novel
hESC lines:
d Human pluripotent stem cell registry of the European Union
(hPSCreg): https://hpscreg.eu/
d hESC registry of the NIH: http://stemcells.nih.gov/research/
registry/
d International Stem Cell Registry of the University of
Massachusetts (UMass) Medical School: https://www.
umassmed.edu/iscr/
d List of acceptably derived embryonic stem cell lines, Califor-
nia Institute for Regenerative Medicine: https://www.cirm.
ca.gov/our-funding/
acceptably-derived-embryonic-stem-cell-lines
d Coriell’s Stem Cell Biobank: https://www.coriell.org/1/
Stem-Cells/Stem-Cell-Services
d eagle-i iPS search tool: https://search.eagle-i.net/central/
iPSCellSearch.html
d Integrated Collection of Stem Cell Bank data by MIACARM
(ISCBI): http://icscb.stemcellinformatics.org/
d UK Stem Cell Bank: http://www.nibsc.org/ukstemcellbank
d Canadian National Registry of Human Embryonic Stem Cell
Lines: http://www.cihr-irsc.gc.ca/e/39580.html
d Korean Stem Cell Bank: http://www.cdc.go.kr/CDC/eng/
contents/CdcEngContentView.jsp?cid=60433&menuIds=
HOME002-MNU1628-MNU1629-MNU1631
d Stem Cell Bank of Barcelona: https://www.cmrb.eu/banco-
lineas-celulares/en_index.htmld ListofhESC linesderived inFrance,Agencede laBiome´decine:
https://www.agence-biomedecine.fr/liste-et-caracteristiques?
lang=fr
d Andalusian Stem Cell Bank, Biobanco del Sistema
Sanitario Pu´blico de Andalucı´a: http://www.juntadeandalucia.
es/salud/biobanco/servicios/provision?hijo=356
d Stem Cell Repository of the New York Stem Cell Foundation:
https://nyscf.org/research-institute/
repository-stem-cell-search/
d University of Connecticut-Wesleyan University Stem Cell
Core: https://health.uconn.edu/stem-cell-core/
d WiCell Stem Cell Bank: https://www.wicell.org/home/
stem-cell-lines/stem-cell-lines.cmsx
d Genea Biocells Stem Cell Bank: http://geneabiocells.com/
technology-platform/stem-cell-bank/
Furthermore, additional public information on novel hESCs
released in the press was obtained by continuously examining
Google News Alerts containing the terms ‘‘stem cell’’ or ‘‘stem
cells.’’
To determine hESC usage in individual studies, full text and
supplementary information of hESC research papers were manu-
ally inspected. Sublines (e.g., clonal derivatives or genetically
modified sublines) were allocated to the respective parental
hESC line.
Determination of Clinical Trials Involving hPSCs
Clinical trials were identified by screening the ClinicalTrials.gov,
by the US National Library of Medicine (https://clinicaltrials.
gov/) and the International Clinical Trials Registry Platform
of the World Health Organization (http://apps.who.int/
trialsearch/). In addition, the sponsor’s Web pages were evalu-
ated for additional information on the respective clinical trials,
and public information in the press was obtained by continu-
ously examining Google News Alerts containing the terms
‘‘stem cell’’ or ‘‘stem cells’’ and ‘‘clinical trials.’’
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